Pigment Epithelial Detachment: Causes, Symptoms & Treatment

Pigment epithelial detachment, often shortened to PED, occurs when the retinal pigment epithelium (RPE), a thin cell layer at the back of the eye, lifts away from Bruch’s membrane beneath it. The separation can be filled with fluid, blood, or accumulated cellular debris, and the type of filling largely determines how much trouble it causes. PED is most commonly linked to age-related macular degeneration (AMD) but also shows up in other conditions, and its behavior ranges from quietly stable to vision-threatening depending on what is driving it.

What Causes a PED to Form

The RPE sits on Bruch’s membrane like wallpaper on a wall. Over a lifetime, metabolic waste products accumulate in and under Bruch’s membrane, gradually reducing its ability to let fluid pass through. That fluid backup, combined with deposits called drusen building up beneath the RPE, can slowly push the cell layer upward and away from its foundation.¹ In cases involving “wet” AMD, abnormal blood vessels grow through breaks in Bruch’s membrane and leak fluid or blood into the space beneath the RPE, further inflating the detachment.

AMD is the most frequent culprit, but not the only one. A study categorizing 53 eyes with PED found that roughly 30% were linked to a group of conditions called the pachychoroid spectrum (characterized by an abnormally thick choroid, the vascular layer behind the retina), about 28% to wet AMD, nearly 19% to central serous chorioretinopathy (CSC), about 11% to dry AMD, and about 11% to polypoidal choroidal vasculopathy (PCV).² Each underlying disease drives PED formation through slightly different pathways, which matters because the treatment approach depends heavily on what is actually happening beneath the detachment.

The Different Types of PED

Not all PEDs look or behave the same on imaging. Clinicians generally group them by what fills the space between the RPE and Bruch’s membrane, and this classification has real consequences for how aggressively the detachment needs to be treated.

Drusenoid PED: This forms when soft drusen merge under the macula. One long-standing definition describes it as confluent soft drusen spanning at least half a disc diameter beneath the center of the macula.³ These detachments tend to grow slowly, carry a lower risk of sudden vision loss, and are generally associated with the dry form of AMD. However, they can progress to either wet AMD or geographic atrophy over time.
Serous PED: Clear fluid collects under the RPE, often in the setting of CSC, where abnormal leakiness from choroidal vessels forces fluid upward. Serous PEDs tend to produce a smooth, dome-shaped elevation on imaging. They can also appear in early wet AMD.
Vascularized (fibrovascular) PED: Abnormal new blood vessels, known as choroidal neovascularization, grow into the sub-RPE space. These vessels leak and bleed, making this the most treatment-urgent type. Imaging studies show that neovascularization is present in the vast majority of vascularized PEDs.²
Hemorrhagic PED: Blood pools under the RPE, sometimes dramatically. This can happen in PCV, where abnormal polyp-like vascular structures rupture. Hemorrhagic PEDs occasionally become massive, spanning dozens of disc areas, and may require surgery if they do not respond to injections alone.⁴

These categories are not always clean-cut. Some eyes have mixed PEDs with features of more than one type, and the classification can shift as the disease evolves. A PED that starts as serous can become vascularized if new blood vessels develop.

Where Central Serous Chorioretinopathy Fits In

CSC deserves its own mention because it is one of the more common non-AMD causes of PED, and it tends to affect a younger demographic, often adults in their 30s through 50s. In CSC, the choroid becomes abnormally thick and leaky, and fluid collects under the RPE. The detachments in CSC are typically serous, but a subset of patients develop flat, irregularly shaped PEDs that behave differently from the typical focal dome. Research has found that patients with these irregular PEDs have longer symptom durations, thicker choroids, and a higher likelihood of hidden neovascularization underneath. This has led some researchers to reclassify CSC with flat irregular PED as a form of pachychoroid neovasculopathy, essentially a bridge between a benign fluid leak and a truly neovascular condition.⁵

There is even a genetic dimension. A study comparing CSC patients with and without irregular PEDs found that a variant in the CFH gene, which is well known for its role in AMD susceptibility, was significantly more common in the irregular-PED group. In fact, the genetic profile of CSC patients with irregular PEDs looked more like that of patients with neovascular AMD than like typical CSC patients.⁶ This matters practically because these patients may need closer monitoring and earlier treatment.

What Symptoms to Expect

Small PEDs can be completely silent. Many people have no idea anything is happening under their retina until an eye exam reveals it. When a PED does produce symptoms, they center on central vision because the macula is where PEDs most commonly develop. Visual distortion is the hallmark complaint. Straight lines, such as doorframes or text, may appear bent or wavy. One case report describes a patient presenting specifically with distortion in one eye, and imaging revealed a PED beneath the fovea.⁷

Other symptoms include a blurred or dark spot in the center of vision, difficulty reading or recognizing faces, and a sense that colors look faded. The severity depends on the PED’s location, height, and whether there is fluid leaking into the surrounding retina. A tall, actively leaking vascularized PED sitting right under the fovea can cause significant vision loss. A flat drusenoid PED slightly off-center may produce nothing noticeable for years. The crucial takeaway is that new-onset distortion or a central blur warrants a prompt eye exam, because some PEDs require treatment quickly to prevent permanent damage.

How PED Is Diagnosed

The gold standard for spotting a PED is optical coherence tomography, or OCT, a non-invasive scan that produces cross-sectional images of the retina in fine detail. On OCT, a PED appears as a dome-shaped or irregular elevation of the RPE away from Bruch’s membrane. The contents of the space underneath help classify the type: serous PEDs appear as a relatively uniform dark void, fibrovascular PEDs show mixed bright and dark material, and drusenoid PEDs have a more granular internal texture.

OCT alone does not always reveal the whole picture, though. Multiple imaging tools contribute different information. OCT angiography can map blood flow beneath the PED to detect hidden neovascularization without requiring a dye injection. Fluorescein angiography, which uses a dye injected into a vein, shows leakage patterns that help distinguish between active and quiet disease. Indocyanine green angiography penetrates deeper into the choroid and is particularly useful for identifying polypoidal vascular changes. Autofluorescence imaging highlights RPE dysfunction patterns, and infrared imaging assists in evaluating the RPE surface.⁸ In practice, a retina specialist will choose the combination of tests that best fits the clinical scenario rather than ordering everything at once.

Automated detection is an emerging area. Deep-learning algorithms have been trained to identify drusenoid PEDs from OCT scans by segmenting the RPE and Bruch’s membrane layers and flagging areas where the separation exceeds defined thresholds.⁹ Similar AI systems have been developed to quantify fluid volumes and predict future treatment needs, which could eventually help clinics schedule follow-ups more efficiently.¹⁰

Treatment With Anti-VEGF Injections

For vascularized and serous PEDs associated with wet AMD, anti-VEGF injections into the eye are the front-line treatment. These drugs block a protein called vascular endothelial growth factor that drives the growth of abnormal blood vessels and promotes fluid leakage. When the leaking vessels quiet down, the PED often shrinks or flattens.

Results from the HARBOR trial showed that about 36% of patients with a PED at baseline achieved complete flattening of the detachment after just one ranibizumab injection. By the second month, an additional 17% had flattened as well, meaning over half of patients saw their PED resolve within the first two injections.¹¹ These are encouraging numbers, but they also mean that a sizable portion of patients need ongoing injections and additional time before achieving meaningful PED reduction.

Newer agents are refining these outcomes. Faricimab, which targets both VEGF and angiopoietin-2, showed greater reductions in maximum PED thickness compared to aflibercept at 12 weeks in a head-to-head comparison. The difference was especially pronounced in serous PEDs and large PEDs, and the proportion of serous PEDs that remained serous at week 12 was markedly lower with faricimab (about 5% versus about 13% with aflibercept).¹² For eyes that have stopped responding to one anti-VEGF drug, switching to another can sometimes restart progress. A study of eyes resistant to high-dose aflibercept found that switching to standard-dose faricimab significantly reduced PED volume, particularly after the first two injections. Interestingly, doubling the faricimab dose did not add benefit, suggesting a ceiling effect at the standard dose.¹³

Treatment for PCV and Stubborn Cases

Polypoidal choroidal vasculopathy presents a somewhat different treatment picture. PCV involves abnormal vascular networks with polyp-like dilations beneath the RPE, and it can produce large, sometimes hemorrhagic PEDs. Anti-VEGF monotherapy works, but landmark studies (EVEREST-II and PLANET) demonstrated that combination therapy, pairing anti-VEGF injections with photodynamic therapy, yields excellent anatomical and visual outcomes.¹⁴ Photodynamic therapy involves injecting a light-sensitive drug into the bloodstream and then activating it with a low-power laser targeted at the abnormal vessels, selectively shutting them down without damaging surrounding tissue.

When hemorrhagic PEDs become massive, surgery may be necessary. A case report described two PCV patients with hemorrhagic PEDs larger than 50 disc areas who underwent vitrectomy combined with a clot-dissolving drug injected beneath the retina, an anti-VEGF injection, and a gas bubble to hold the retina in place. Both achieved rapid flattening of their PEDs.⁴ These surgical approaches are reserved for extreme cases and carry their own risks, but they offer an option when injections alone cannot manage the situation.

For serous PEDs that resist standard intravitreal anti-VEGF injections, early research has explored injecting the drug into the suprachoroidal space, the area just behind the choroid. One small study reported that suprachoroidal bevacizumab reduced PED size and height in all treated patients.¹⁵ This delivery route is still experimental for PED specifically, but the concept of getting the drug closer to the disease target is gaining traction in retinal care more broadly.

RPE Tears as a Complication

One of the more feared complications associated with PED is an RPE tear, where the stretched pigment epithelium literally rips. This can happen spontaneously as the PED enlarges, but it also happens after anti-VEGF injections, particularly in the early phase of treatment. The mechanism appears to involve the neovascular tissue adhering to the undersurface of the RPE. When the drug causes that tissue to contract rapidly, it pulls on the already-stretched RPE, and the cell layer ruptures along a segment that lacks adhesion to either the neovascular tissue or Bruch’s membrane.¹⁶

The overall risk is relatively small. A retrospective series of 375 eyes with PEDs found that about 3% developed an RPE tear, and the rate was similar regardless of which anti-VEGF drug was used. Most tears occurred early, with 30% happening after the first injection and 50% after the second. Notably, the eyes that tore tended to have tall PEDs, averaging roughly 595 micrometers in height. Visual outcomes varied: about two-thirds of affected eyes maintained or improved their vision, while a minority experienced meaningful vision loss.¹⁷ This means that while RPE tears are a real risk, they are uncommon and do not always lead to devastating visual outcomes. Clinicians often weigh the height and characteristics of a PED before initiating treatment, as very tall or heavily vascularized PEDs carry higher tear risk.

Long-Term Outcomes and Geographic Atrophy

Even when treatment successfully flattens a vascularized PED, the long-term outlook is not guaranteed. One under-recognized concern is the development of geographic atrophy, an irreversible loss of RPE cells and the photoreceptors they support, in the area where the PED once sat. Research has documented that when a PED reabsorbs or flattens, the photoreceptor outer segments beneath it can disappear, and the number of inner segments drops. This process leads to gradual vision loss even after the structural problem has been corrected.¹⁸

This creates a frustrating paradox. The goal of treatment is to flatten the PED and dry up the fluid, but the very process of flattening can reveal or hasten atrophy in the underlying tissue. It does not mean treatment is counterproductive; untreated vascularized PEDs cause damage too, often more of it. But it explains why some patients feel that their vision plateaued or even worsened slightly even after their retina specialist declared the PED resolved on the scan. The damage from the detachment itself, accumulated during the months or years it was present, may become more apparent once the PED is no longer masking the atrophic tissue underneath.

What Happens Inside a Vascularized PED Over Time

Vascularized PEDs are not static structures. Imaging research that tracked these detachments over time using three-dimensional analysis found two broad patterns of progression. Some evolved into what researchers call a “filled” multilayered state, where the neovascular tissue layers organize and the PED shrinks in height and volume. These tended to require fewer anti-VEGF injections and appeared to represent a more stable end state. Others persisted as unstable fluid-filled cavities that maintained their height and volume despite treatment, suggesting ongoing active leakage.¹⁹ For patients and clinicians, the takeaway is that not every PED responds the same way, and the internal architecture matters at least as much as the external dimensions.

Monitoring at Home Between Visits

Because PEDs can change between clinic appointments, home monitoring plays a practical role. The traditional tool is the Amsler grid, a square grid of lines with a central dot. You look at it with one eye at a time, and if any of the lines appear wavy, broken, or missing, it can signal new or worsening distortion in your central vision. The test is simple but far from perfect; it depends entirely on the person remembering to do it and noticing subtle changes.

Newer app-based tools have started to replace the paper grid. Applications such as Alleye, the Amsler Grid App, and FoveApp build in features like reminders, standardized lighting conditions, and secure data storage so both you and your eye specialist can review trends over time.²⁰ None of these replace in-clinic OCT, but they can help catch changes earlier and trigger a visit before a PED has had weeks or months of unmonitored growth. If you have a known PED or a condition that puts you at risk for one, asking your retina specialist about home monitoring options is a reasonable step.